Gene mutations in the EGFR signaling pathway, such as mutations in KRAS, NRAS, BRAF and PIK3CA, have become an important part of CRC evaluation, and their alterations may determine the therapeutic response to anti-EGFR therapy12, 13. This evidence concerns the gene KRAS and colorectal carcinoma.